Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of a lead-in study (NCT00891462)
You may not be if
Use or anticipated use of any medication prohibited in this study
Evidence of abnormal clinical laboratory values, vital signs, or electrocardiographic (ECG) results or the presence of abnormities in physical examination findings
The presence of anti-cholinergic effects (eg, dry mouth, urinary retention, narrow angle glaucoma)
QTcB of \>500 msec on both the pre-dose and post-dose ECG
Women who are pregnant, intend to become pregnant, or are breast-feeding
A life expectancy of less than 1 year
Noncompliance with IP dosing and/or attending clinic visits during the lead-in study
Significant interruption of double-blind therapy during the transition from the lead-in study into the extension study.
Clareo Health | Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
